Document is current
Any future updates will be listed below
-
Authors
Leiter, Lawrence A.
Bain, Stephen C.
Hramiak, Irene
Jódar, Esteban
Madsbad, Sten
Gondolf, Theis
Hansen, Thomas
Holst, Ingrid
Lingvay, Ildiko
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01720446 at ClinicalTrials.govDocuments that mention this clinical trial
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6
https://doi.org/10.1186/s12933-022-01489-6
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
https://doi.org/10.1161/strokeaha.121.037775
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
https://doi.org/10.1186/s12933-019-0871-8
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 31 March 2019
Accepted: 17 May 2019
First Online: 6 June 2019
Ethics approval and consent to participate
: The protocol was approved by local ethics committees and institutional review boards at each participating center. All subjects provided written informed consent.
: Not applicable.
: During the conduct of the study, L.A.L. received research grants to his institution from Novo Nordisk. Outside of the submitted work, he has received grants and/or personal fees for advisory panels, speakers’ bureaus, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. He also reports research grants from GlaxoSmithKline and personal fees for advisory panels from Servier.Outside the submitted work, S.C.B. has received honoraria, teaching, and research sponsorship/grants from Abbott, AstraZeneca, Boehringer Ingelheim, Cellnovo, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-aventis, Cardiff University, Doctors.net, Elsevier, Onmedica, Omnia-Med, Medscape, All-Wales Medicines Strategy Group, National Institute for Health and Care Excellence (NICE) UK, and Glycosmedia.Outside the submitted work, I.H. reports research grants and/or personal fees from AstraZeneca/Bristol-Myers Squibb, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline, Insulet Corp, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Medtronic, Merck & Co Inc, Population Health Research Institute, Roche Pharma, Sanofi, and Takeda.E.J. reports grants and personal fees from Novo Nordisk during the conduct of the study. He also reports grants and personal fees as a consultant and/or speaker from Amgen, AstraZeneca, Boehringer Ingelheim, Faes Farma, Fresenius, Janssen Pharmaceuticals, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and UCB.Outside of the submitted work, S.M. has received honoraria and/or lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, Intarcia Therapeutics, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi Aventis. He has also received a research grant from Novo Nordisk and Boehringer Ingelheim.T.G., T.H., and I.H. report that they are full-time employees of Novo Nordisk A/S.I.L. received research grants to her institution and consulting fees from Novo Nordisk during the conduct of the study. Outside the submitted work, she has received grants and/or personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia, Mannkind, Merck, Mylan, Novartis, NovoNordisk, Pfizer, Sanofi, TARGETPharma, and Valeritas.
